Head-to-head · Value Score
bmiMD vs AM Rx
Two GLP-1 deals, scored on the same six factors. bmiMD lands a Value Score of 89, AM Rx a 55. Here's who gives you the honest lower price — and where each one bites back.
bmiMD
#11 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameAM Rx
#373 · Grade C · Watch List
Est. first month
From $151/mo (quarterly plan, plus a separate fee, compounded)
Save ~89% vs brand-nameThe verdict
bmiMD takes it on Value Score, 89 to 55 — an est. $99/mo first month, with no teaser step-up baked in. AM Rx isn't out of it: Patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully).
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | bmiMD | AM Rx |
|---|---|---|
| Value Score | 89 (A) | 55 (C) |
| Est. first month | $99/mo | From $151/mo (quarterly plan, plus a separate fee, compounded) |
| Save vs brand-name | ~93% | ~89% |
| Semaglutide | $99/mo | From $151/mo (quarterly plan, plus a separate fee, compounded) |
| Tirzepatide | $139/mo | Not disclosed |
| Both molecules | Yes | No |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
bmiMD
Sub-$100 semaglutide and a low $139 tirzepatide, flat and nationwide — a straight-up low-price play.
Why it's a deal
- $99 flat semaglutide and a low $139 tirzepatide
- Available in all 50 states
- Both molecules priced up front
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Thin public track record; no oral or brand-name option
AM Rx
AM Rx (getamrx.com) is a telehealth platform operated by FitRX, LLC (also operates Zealthy and FitRx).
Why it's a deal
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
The fine print
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores bmiMD is ranked on the bmiMD alternatives board, and the same list for the other side is on alternatives to AM Rx.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.